Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

QPS Mra LLC

Neither a doctor nor a teaching hospital

Research payments

$37,482,118

388 payments

Through program year 2025, QPS Mra LLC is reported as receiving $37,482,118 in research payments, across 388 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $5,375,719 30
2024 Research $7,659,892 37
2023 Research $2,521,843 37
2022 Research $4,307,208 50
2021 Research $8,948,491 76
2020 Research $2,708,498 68
2019 Research $5,960,466 90

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $25,702,151 240 payments
  2. Amgen Inc. $4,553,183 8 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $3,147,301 22 payments
  4. Merck Sharp & Dohme Corporation $955,853 11 payments
  5. Noven Pharmaceuticals, Inc. $671,471 12 payments
  6. Janssen Research & Development, LLC $665,735 11 payments
  7. Upsher-Smith Laboratories LLC $611,317 19 payments
  8. AstraZeneca Pharmaceuticals LP $356,619 2 payments
  9. Eli Lilly and Company $231,670 2 payments
  10. GlaxoSmithKline, LLC. $217,588 30 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Twopart Phase 1 Openlabel Fixedsequence Study to Evaluate the Multiple Dose Pharmacokinetics of Danuglipron Following Oral Administration and the Effects of Steadystate Danuglipron on the Pharmacokinetics of Single Oral Dose of Atorvastatin and Rosuvastatin in Otherwise Healthy Adult Participants With Overweight Or Obesity $7,921,481 14 payments
  2. A Phase 1 Randomized Doubleblind Sponsoropen Placebocontrolled Study to Assess the Safety Tolerability and Pharmacokinetics of Multiple Escalating Oral Doses of Pf06954522 in Adult Participants With Type 2 Diabetes Mellitus $4,448,502 6 payments
  3. A Phase 1 Randomized Doubleblind Sponsoropen Placebocontrolled Study to Assess the Safety Tolerability and Pharmacokinetics of Multiple Oral Doses of Pf07081532 in Adult Participants With Type 2 Diabetes Mellitus $3,729,789 13 payments
  4. A Phase 1 Randomized Doubleblind Sponsoropen Placebocontrolled Study to Assess the Safety Tolerability and Pharmacokinetics of Multiple Escalating Oral Doses of Pf07081532 in Adult Participants With Type 2 Diabetes Mellitus $2,486,434 19 payments
  5. Single-Blind; Single Dose; 2-Arm; Parallel Group to Determine Pharmacokinetic Equivalence $2,390,346 1 payment
  6. A Phase 1 Openlabel Fixedsequence Study to Estimate the Effect of Pf07081532 Administration on the Singledose Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight Or Obese Adult Participants $1,769,353 13 payments
  7. A Phase 1 Randomized Doubleblind Sponsoropen Placebocontrolled Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Multiple Escalating Oral Doses of Pf06882961 in Adult Subjects With Type 2 Diabetes Mellitus $1,343,954 10 payments
  8. AMG 598-Ph 1 Safety; Tolerability; PK and PD of MAD $1,316,379 2 payments
  9. BAY1237592 MD study $1,159,247 4 payments
  10. A Phase 1 Randomized Doubleblind Sponsoropen Placebocontrolled Firstinhuman Study to Evaluate the Safety Tolerability and Pharmacokinetics of Single Ascending Oral Doses of Pf07258669 Administered to Healthy Adult Participants $1,112,275 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record